company background image
CCXI

ChemoCentryxNasdaqGS:CCXI Stock Report

Market Cap

US$2.5b

7D

-8.4%

1Y

-35.0%

Updated

26 Nov, 2021

Data

Company Financials +
CCXI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CCXI Stock Overview

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.

ChemoCentryx Competitors

AbbVie

NYSE:ABBV

US$206.0b

Amgen

NasdaqGS:AMGN

US$113.3b

Biogen

NasdaqGS:BIIB

US$35.7b

Incyte

NasdaqGS:INCY

US$15.1b

Price History & Performance

Summary of all time highs, changes and price drops for ChemoCentryx
Historical stock prices
Current Share PriceUS$36.28
52 Week HighUS$70.29
52 Week LowUS$9.53
Beta1.83
1 Month Change11.19%
3 Month Change130.64%
1 Year Change-34.99%
3 Year Change261.00%
5 Year Change344.61%
Change since IPO229.82%

Recent News & Updates

Oct 09
Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Sep 29

ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way

ChemoCentryx is developing Avacopan - a C5 complement receptor inhibitor - for several autoimmune conditions. The company has an upcoming PDUFA date for Avacopan in ANCA vasculitis - the FDA will make its decision on whether to approve the drug on October 7th. The original date was July 2021 but the decision was delayed after ChemoCentryx provided additional data. An FDA Adcom was split over an approval verdict in May. ChemoCentryx stock traded at $68 prior to the Adcom and PDUFA date delay, based on a $1.9bn peak sales potential. Today, shares trade at $20. Avacopan won approval in Japan this week - an encouraging sign - but I suspect the FDA may reject the therapy this time around, and that ChemoCentryx market valuation will fall further as a result - it will be a marginal decision.

Aug 24

ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends

Most expected CCXI to have achieved regulatory approval for avacopan to treat ANCA-Associated Vasculitis on July 7, 2021. Regulatory review is ongoing with the PDUFA extended to Oct. 6, 2021, in response to new filing by CCXI which the FDA designated as a major amendment to the NDA. The good news is that CCXI has not been issued the dreaded complete response letter. The outcome of the PDUFA is dependent on a satisfactory rebuttal to the Adcom questions and comments. Read on for details on the potential regulatory review outcome.

Shareholder Returns

CCXIUS BiotechsUS Market
7D-8.4%0.4%-2.7%
1Y-35.0%5.3%21.3%

Return vs Industry: CCXI underperformed the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: CCXI underperformed the US Market which returned 21.3% over the past year.

Price Volatility

Is CCXI's price volatile compared to industry and market?
CCXI volatility
CCXI Average Weekly Movement28.4%
Biotechs Industry Average Movement8.6%
Market Average Movement5.9%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.2%

Stable Share Price: CCXI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 28% a week.

Volatility Over Time: CCXI's weekly volatility has increased from 19% to 28% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996133Thomas Schallhttps://www.chemocentryx.com

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease.

ChemoCentryx Fundamentals Summary

How do ChemoCentryx's earnings and revenue compare to its market cap?
CCXI fundamental statistics
Market CapUS$2.54b
Earnings (TTM)-US$121.10m
Revenue (TTM)US$34.27m

74.1x

P/S Ratio

-21.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CCXI income statement (TTM)
RevenueUS$34.27m
Cost of RevenueUS$85.45m
Gross Profit-US$51.18m
ExpensesUS$69.92m
Earnings-US$121.10m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.73
Gross Margin-149.35%
Net Profit Margin-353.41%
Debt/Equity Ratio7.5%

How did CCXI perform over the long term?

See historical performance and comparison

Valuation

Is ChemoCentryx undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CCXI ($36.28) is trading below our estimate of fair value ($109.4)

Significantly Below Fair Value: CCXI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CCXI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CCXI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CCXI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CCXI is overvalued based on its PB Ratio (8x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is ChemoCentryx forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

64.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CCXI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: CCXI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CCXI's is expected to become profitable in the next 3 years.

Revenue vs Market: CCXI's revenue (51.5% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: CCXI's revenue (51.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CCXI is forecast to be unprofitable in 3 years.


Past Performance

How has ChemoCentryx performed over the past 5 years?

-33.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CCXI is currently unprofitable.

Growing Profit Margin: CCXI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CCXI is unprofitable, and losses have increased over the past 5 years at a rate of 33.1% per year.

Accelerating Growth: Unable to compare CCXI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CCXI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: CCXI has a negative Return on Equity (-38.34%), as it is currently unprofitable.


Financial Health

How is ChemoCentryx's financial position?


Financial Position Analysis

Short Term Liabilities: CCXI's short term assets ($293.4M) exceed its short term liabilities ($60.0M).

Long Term Liabilities: CCXI's short term assets ($293.4M) exceed its long term liabilities ($78.9M).


Debt to Equity History and Analysis

Debt Level: CCXI has more cash than its total debt.

Reducing Debt: Insufficient data to determine if CCXI's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CCXI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CCXI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is ChemoCentryx current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CCXI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CCXI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CCXI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CCXI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CCXI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Thomas Schall (62 yo)

24.83yrs

Tenure

US$8,366,309

Compensation

Dr. Thomas J. Schall, Ph.D. Founded ChemoCentryx Inc. in November 1996 and has been its Chief Executive Officer and President since 1997. Dr. Schall focuses on the discovery and development of chemokine-ba...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD8.37M) is above average for companies of similar size in the US market ($USD5.20M).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CCXI's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: CCXI's board of directors are considered experienced (7.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ChemoCentryx, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: ChemoCentryx, Inc.
  • Ticker: CCXI
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.541b
  • Shares outstanding: 70.03m
  • Website: https://www.chemocentryx.com

Number of Employees


Location

  • ChemoCentryx, Inc.
  • 835 Industrial Avenue
  • Suite 600
  • San Carlos
  • California
  • 94070
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/26 23:04
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.